Donald Santel


Donald Santel served as Chief Executive Officer of Hyperion Therapeutics (Nasdaq GM: HPTX) from June 2008 until the sale of the company to Horizon Pharma (Nasdaq GM: HZNP) for $1.1B in May 2015. In leading Hyperion, he was responsible for all aspects of the business taking it from a development stage private company, through the approval and commercial launch of Ravicti for the treatment of urea cycle disorders. Hyperion achieved and maintained profitability in each of its 10 quarters as a public company. Mr. Santel was a member of Hyperion’s Board of Directors from March 2007 through the company’s sale.

Previously, Mr. Santel was a member of the board of directors and the Chief Executive Officer of CoTherix, Inc., (Nasdaq GM: CTRX) a biopharmaceutical company he co-founded in 2000 and brought public in 2004, where he was responsible for the oversight of all aspects of the business and led the sale of the company to Actelion for $419M in January 2007.

Prior to joining CoTherix, Mr. Santel was employed by or consultant to several medical device companies, including Reflow, Inc., Cardiac Pathways Corporation and Medtronic, Inc. Mr. Santel serves on the board of directors of OlympEX Medical, a medical device company. Mr. Santel previously served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc. and as a director of ChemGenex Pharmaceuticals, Inc. Mr. Santel holds an M.S. in electrical engineering from the University of Minnesota and a B.S.E. in biomedical engineering from Purdue University.


Co-founder and Chief Executive Officer of NeuroRecovery Technologies. A serial entrepreneur with 27 years of experience in the various disciplines of the Life Science Industry touching upon every facet in the healthcare delivery system from clinical practice, and product development to healthcare provider programs. Founder & CEO Freedom Health, LLC; Co-founder and CEO Spectrum Mobile Diagnostics; Medical Director Medisens Wireless.


Member of Board
Dr. Burdick is the Richard L. and Dorothy M. Hayman Professor of Mechanical Engineering and Bioengineering at The California Institute of Technology. A faculty member at Cal Tech since 1988 Professor Burdick is known for his work in robotics, control systems and applied algorithms to mechanical and biological systems applying nearly 30 years experience. Professor Burdick has also worked in the area of Brain-Machine Interfaces for over a decade with Prof. Richard Anderson at Caltech, and has collaborated with Prof. Edgerton in the area of spinal cord injury research for more than ten years.


Member of Board

As a Certified Public Accountant with emphasis in business finance, Mr. Langdale began his career with Price Waterhouse after graduating from UCLA, Magna Cum Laude in Economics & Business. Following Price Waterhouse, Mr. Langdale held financial management roles with several medical device and service companies; with the most notable being the CFO of Masimo Corporation, an Irvine, CA, based non-invasive patient monitoring company. While at Masimo he secured five rounds of private funding totally approximately $80 million and completed one of the most successful IPO’s of 2007.

During his tenure, revenues grew from $0 to $240 million and the company’s valuation increased from $25 million to over $1 billion. Mr. Langdale is presently serving also as a member of the Board of Conformis, Inc., Bedford, MA a publicly traded medical device company that develops novel, proprietary orthopedic implants. Since joining the Conformis Board in 2008, the company successfully commercialized its products, reaching a current run rate of over $80 million, and completed its IPO in 2015.


Member of Board

Mr. Shepard has more than 33 years of experience across pharmaceutical, biotechnology and drug delivery companies, most recently as an Executive Partner at Sofinnova Ventures, a healthcare focused venture capital firm, where he leveraged his industry expertise in support of the firm’s portfolio companies and served as Executive Chairman of the Versartis Board of Directors since early 2014, before taking on the role of CEO in May of 2015.

Previously, he was President and CEO of NextWave Pharmaceuticals, a pediatric focused company acquired by Pfizer; President and CEO of Ilypsa, a nephrology company acquired by Amgen; and interim President and CEO of Relypsa (Ilypsa’s spin-out company). Mr. Shepard has extensive commercial experience, helping led over 17 product launches and establishing and coordinating multiple sales and marketing operations. He previously served as Vice President of Commercial Operations at Telik, where he oversaw all commercialization and market planning activities for the company’s oncology programs. Jay was one of the early commercial executives at Alza Pharmaceuticals where he was Vice President in the Commercial Operations group, having held leadership roles of increasing responsibility in its establishment, operations and commercial presence. Alza was acquired by Johnson & Johnson in late 2001. He began his career in the pharmaceutical industry at Johnson & Johnson and Syntex Labs.

Jay is a board member of The Christopher & Dana Reeve Foundation, Durect Corporation, Marinus Pharmaceuticals and the Santa Clara University Entrepreneurial School. Jay holds a BS in Business Administration from the University of Arizona.

  • Author:
  • Date:
  • Source: